Committees
Protocol Review and Monitoring Committee
The membership of the Protocol Review and Monitoring Committee (PRMC) has been designed to provide broad representation from the various oncology subspecialties, including community oncology, and support areas critical to the success of a clinical research enterprise. This broad representation is necessary to provide high quality and thorough protocol review. All members of the PRMC are full voting members. The Co-Directors of the Cancer Center are ex officio members. The committee meets monthly. See a detailed schedule of committee meeting dates.
| Name/Email | Title/Area of Expertise | Phone | Information |
|---|
| Christopher Anker, M.D. | PRMC Chair
Assistant Professor
Radiation Oncology | (802) 847- 3506 | |
| Jessica Heath, M.D. | PRMC Vice Chair
Pediatric Cancer
(Hematology/Oncology)
UVM Medical Center Children's Hospital | | |
| Steven Ades, M.D. | Associate Professor
Medical Oncology | (802) 656-5451 | Bio |
| Dmitriy Akselrod, M.D. | Diagnostic Radiologist | | |
Rob Cade, Pharm.D. | Oncology Pharmacist | (802) 847-5577 | |
| Frances Carr, Ph.D. | UVM Larner College of Medicine, Pharmacology | | |
| Kim Dittus, M.D. | Ad-Hoc PRMC Member UVM Medical Center Hematology/Oncology: Breast | | |
| Janet Ely, A.P.R.N | Hematology/Oncology Nurse Practitioner | | |
| Mark Evans, Ph.D. | Assistant Professor
Pathology | (802) 656-3628 | |
| Eric Ganguly, M.D. | Gastroenterology | | |
Alan Howe, Ph.D.
| Professor
Pharmacology | (802) 656-9521 | |
| Anthony Minichiello, R.N. | UVM Cancer Center Research Nurse Supervisor | | |
Shelly Naud, Ph.D.
| Researcher Analyst
Biostatistics | (802) 656-3822 | |
Scott Perrapato, D.O.
| Associate Professor
Urology | (802) 847-2884 | Bio |
Karen Wilson, C.C.R.P.
| Clinical Trials Supervisor, UVM Cancer Center | (802) 656-4101 | |
Clinical Research Oversight Committee
The Clinical Research Oversight Committee (CROC) was a senior leadership committee charged with the responsibility for Data and Safety Monitoring. All clinical trials require monitoring, which is performed on a regular basis and is commensurate with the risk and size of the trial. The committee met quarterly. The CROC will be replaced with a Data Safety and Monitoring Committee and will be announced mid-2016.